DK0624595T3 - Nor-galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler - Google Patents

Nor-galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler

Info

Publication number
DK0624595T3
DK0624595T3 DK94106846T DK94106846T DK0624595T3 DK 0624595 T3 DK0624595 T3 DK 0624595T3 DK 94106846 T DK94106846 T DK 94106846T DK 94106846 T DK94106846 T DK 94106846T DK 0624595 T3 DK0624595 T3 DK 0624595T3
Authority
DK
Denmark
Prior art keywords
compounds
processes
acid derivatives
drugs
preparation
Prior art date
Application number
DK94106846T
Other languages
Danish (da)
English (en)
Inventor
Alfons Dr Enhsen
Heiner Dr Glombik
Werner Dr Dr Kramer
Guenther Dr Wess
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Application granted granted Critical
Publication of DK0624595T3 publication Critical patent/DK0624595T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0011—Unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C07J41/0027—Azides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
    • C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0066—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by a carbon atom forming part of an amide group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
    • C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/0065—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified
    • C07J7/007—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by an OH group free esterified or etherified not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK94106846T 1993-05-08 1994-05-02 Nor-galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler DK0624595T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4315370 1993-05-08

Publications (1)

Publication Number Publication Date
DK0624595T3 true DK0624595T3 (da) 1999-05-17

Family

ID=6487580

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94106846T DK0624595T3 (da) 1993-05-08 1994-05-02 Nor-galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler

Country Status (17)

Country Link
US (1) US5512558A (cg-RX-API-DMAC7.html)
EP (1) EP0624595B1 (cg-RX-API-DMAC7.html)
JP (1) JPH07316186A (cg-RX-API-DMAC7.html)
KR (1) KR100333150B1 (cg-RX-API-DMAC7.html)
AT (1) ATE169633T1 (cg-RX-API-DMAC7.html)
AU (1) AU669278B2 (cg-RX-API-DMAC7.html)
CA (1) CA2123051C (cg-RX-API-DMAC7.html)
CZ (1) CZ289525B6 (cg-RX-API-DMAC7.html)
DE (1) DE59406637D1 (cg-RX-API-DMAC7.html)
DK (1) DK0624595T3 (cg-RX-API-DMAC7.html)
ES (1) ES2122076T3 (cg-RX-API-DMAC7.html)
FI (1) FI942074L (cg-RX-API-DMAC7.html)
HU (1) HU217446B (cg-RX-API-DMAC7.html)
IL (1) IL109578A (cg-RX-API-DMAC7.html)
NO (1) NO304793B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ260468A (cg-RX-API-DMAC7.html)
TW (1) TW289020B (cg-RX-API-DMAC7.html)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6107494A (en) * 1994-09-13 2000-08-22 G.D. Searle And Company Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
MXPA01006470A (es) * 1998-12-23 2003-06-06 Searle Llc Combinaciones de inhibidores de transporte de acido biliar ileal y agentes de secuentro de acido biliar para indicaciones cardiovasculares.
EP1340510A1 (en) 1998-12-23 2003-09-03 G.D. Searle LLC. Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
DK1140189T3 (da) 1998-12-23 2003-09-15 Searle Llc Kombinationer af ileal galdesyre-transportinhibitorer og fibrinsyrederivater til cardiovaskulære indikationer
US6489366B1 (en) * 1998-12-23 2002-12-03 G. D. Searle, Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
ES2200587T3 (es) * 1998-12-23 2004-03-01 G.D. Searle Llc Combinaciones de inhibidors del transporte de acidos biliares del ileon e inhibidores de la proteina de transferencia de colesteril ester para indicaciones cardiovasculares.
US6462091B1 (en) 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
EP1340509A1 (en) * 1998-12-23 2003-09-03 G.D. Searle LLC. Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
CZ20012344A3 (cs) * 1998-12-23 2002-01-16 G. D. Searle Llc Kombinace pro kardiovaskulární indikace
SE9901387D0 (sv) * 1999-04-19 1999-04-19 Astra Ab New pharmaceutical foromaulations
US20020061888A1 (en) * 2000-03-10 2002-05-23 Keller Bradley T. Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
US6586434B2 (en) 2000-03-10 2003-07-01 G.D. Searle, Llc Method for the preparation of tetrahydrobenzothiepines
US20040077625A1 (en) * 2001-07-25 2004-04-22 Tremont Samuel J. Novel 1,4-benzothiazepine and 1,5-benzothiazepine compounds as inhibitors of apical sodium codependent bile acid transport abd taurocholate uptake
JP2005518347A (ja) * 2001-11-02 2005-06-23 ジー．ディー． サール エルエルシー 頂端ナトリウム共依存性胆汁酸輸送（ａｓｂｔ）およびタウロコール酸塩取り込みの阻害剤としての新規一および二フッ化ベンゾチエピン化合物
US6852753B2 (en) 2002-01-17 2005-02-08 Pharmacia Corporation Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
US7435757B2 (en) * 2004-07-02 2008-10-14 Schering Ag 2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17β-hydroxy steroid dehydrogenase type 1
ES2561614T3 (es) 2005-05-12 2016-02-29 Medizinische Universität Graz Uso de 24-nor-UDCA para el tratamiento de enfermedades hepáticas colestásicas
US20100311708A1 (en) * 2007-07-25 2010-12-09 Tarek Moustafa Use of nor-bile acids in the treatment of arteriosclerosis
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
LT3023102T (lt) 2010-11-04 2018-09-25 Albireo Ab Ibat inhibitoriai, skirti kepenų ligų gydymui
CA2815698C (en) 2010-11-08 2019-04-30 Albireo Ab A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
EP2468762A1 (en) * 2010-11-30 2012-06-27 Dr. Falk Pharma Gmbh Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
EA038594B1 (ru) 2011-10-28 2021-09-21 Шайр Хьюман Дженетик Терапис, Инк. Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
EA201891154A1 (ru) 2011-10-28 2019-02-28 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
RU2015139732A (ru) 2013-03-15 2017-04-24 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециркуляции желчных кислот для лечения пищевода барретта и гастроэзофагеальной рефлюксной болезни
US20140275090A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
US11571431B2 (en) 2013-12-04 2023-02-07 Galmed Research And Development Ltd Aramchol salts
KR20220082931A (ko) 2014-06-25 2022-06-17 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
KR20170094184A (ko) 2014-11-06 2017-08-17 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
KR20170099909A (ko) * 2014-11-26 2017-09-01 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유사체 및 이의 이용 방법
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
SG11201706089RA (en) 2015-02-11 2017-09-28 Enanta Pharm Inc Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
PT3277286T (pt) 2015-03-31 2021-07-01 Enanta Pharm Inc Derivados de ácidos biliares como agonistas de fxr/tgr5 e métodos de utilização destes
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
WO2017138878A1 (en) 2016-02-09 2017-08-17 Albireo Ab Oral cholestyramine formulation and use thereof
CN108601744B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 口服考来烯胺制剂及其用途
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
WO2017147137A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
US10364267B2 (en) 2016-02-23 2019-07-30 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
WO2018102418A1 (en) 2016-11-29 2018-06-07 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
US10472386B2 (en) 2017-02-14 2019-11-12 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR agonists and methods of use thereof
WO2018187804A1 (en) 2017-04-07 2018-10-11 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
CA3071285A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
CA3071182A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine pellets, oral cholestyramine formulations and use thereof
AU2019214347B2 (en) * 2018-02-02 2023-09-28 Ripple Therapeutics Corporation Glass formulations comprising steroid dimers and uses thereof
CN112449637B (zh) 2018-06-05 2024-03-19 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
PL3810581T3 (pl) 2018-06-20 2025-04-28 Albireo Ab Modyfikacje kryształu odewiksibatu
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US12473326B2 (en) 2019-02-01 2025-11-18 Ripple Therapeutics Corporation Crystalline forms of dexamethasone dimers and uses thereof
CA3127408A1 (en) 2019-02-06 2020-08-13 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
SMT202300020T1 (it) 2019-02-06 2023-03-17 Albireo Ab Composti di benzotiadiazepine e loro uso come modulatori degli acidi biliari
EP3923943B1 (en) 2019-02-12 2024-07-31 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
GB201911821D0 (en) 2019-08-16 2019-10-02 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds for use in the treatment of liver disease
WO2021110884A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3158276A1 (en) 2019-12-04 2021-06-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
TWI877263B (zh) 2019-12-04 2025-03-21 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
CR20220315A (es) 2019-12-04 2022-10-26 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores del ácido biliar
AR120679A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar
WO2021110887A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
WO2021110886A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CN114761018B (zh) 2019-12-04 2025-12-02 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CA3176134A1 (en) 2020-05-01 2021-11-04 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders
WO2022029101A1 (en) 2020-08-03 2022-02-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP4188541B1 (en) 2020-08-03 2024-12-25 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
CA3196488A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
EP4255565A1 (en) 2020-12-04 2023-10-11 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
EP4511038A1 (en) 2022-04-22 2025-02-26 Albireo AB Subcutaneous administration of an asbt inhibitor
JP2025524362A (ja) 2022-06-09 2025-07-30 アルビレオ・アクチボラグ 肝炎の処置
AU2023304672A1 (en) 2022-07-05 2025-01-02 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP4629997A1 (en) 2022-12-09 2025-10-15 Albireo AB Asbt inhibitors in the treatment of renal diseases
WO2025146507A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146508A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4104285A (en) * 1977-04-22 1978-08-01 Hoffmann-La Roche Inc. Taurine and glycine derivatives
DE3930696A1 (de) * 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
DE59108326D1 (de) * 1990-12-06 1996-12-12 Hoechst Ag Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindung als Arzneimittel
EP0624593A3 (de) * 1993-05-08 1995-06-07 Hoechst Ag Gallensäurederivate, Verfahren zu ihrer Herstellung und Verwendung dieser Verbindungen als Arzneimittel.
TW289021B (cg-RX-API-DMAC7.html) * 1993-05-08 1996-10-21 Hoechst Ag
TW289757B (cg-RX-API-DMAC7.html) * 1993-05-08 1996-11-01 Hoechst Ag

Also Published As

Publication number Publication date
AU6194694A (en) 1994-11-10
NO941678D0 (no) 1994-05-06
ES2122076T3 (es) 1998-12-16
US5512558A (en) 1996-04-30
IL109578A (en) 1999-08-17
NO941678L (no) 1994-11-09
NZ260468A (en) 1995-02-24
IL109578A0 (en) 1994-08-26
EP0624595A2 (de) 1994-11-17
KR100333150B1 (ko) 2002-09-17
TW289020B (cg-RX-API-DMAC7.html) 1996-10-21
FI942074A0 (fi) 1994-05-05
EP0624595A3 (de) 1995-06-28
HU217446B (hu) 2000-01-28
DE59406637D1 (de) 1998-09-17
CA2123051C (en) 2004-01-20
EP0624595B1 (de) 1998-08-12
NO304793B1 (no) 1999-02-15
CA2123051A1 (en) 1994-11-09
CZ113494A3 (en) 1994-12-15
HUT67653A (en) 1995-04-28
CZ289525B6 (cs) 2002-02-13
AU669278B2 (en) 1996-05-30
FI942074A7 (fi) 1994-11-09
FI942074L (fi) 1994-11-09
ATE169633T1 (de) 1998-08-15
HU9401445D0 (en) 1994-08-29
JPH07316186A (ja) 1995-12-05

Similar Documents

Publication Publication Date Title
DK0624595T3 (da) Nor-galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler
DK0624594T3 (da) Monomere galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemiddel
DK0624596T3 (da) Tetrazolderivater af galdesyrer, fremgangsmåde tilderes fremstilling og anvendelse af disse forbindelser som lægemidler
DK0573848T3 (da) Galdesyrederivater, fremgangsmåde til deres fremstilling og anvendelse af disse forbindelser som lægemidler
DK0530087T3 (da) Hidtil ukendte naphthylethylurinstof- og naphthylethylthiourinstofforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
DK0633259T3 (da) Hidtil ukendte sulfonylaminopyrimidiner, fremstilling heraf og deres anvendelse som lægemidler
NO964700D0 (no) Nye aminosyrederivater, fremgangsmåte til deres fremstilling og farmasöytiske blandinger som inneholder disse forbindelser
NO924433D0 (no) Isoksazol-4-karboksylsyreamider og hydroksyalkyliden-cyaneddiksyreamider, legemidler inneholdende disse forbindelsene og deres anvendelse
FI96204C (fi) Menetelmä terapeuttisesti käyttökelpoisten heterosyklisten yhdisteiden valmistamiseksi
NO883073D0 (no) 3-desmetyl-mevalonsyrederivater, fremgangsmaate til deres fremstilling samt deres anvendelse som mellomprodukter.
NO984290L (no) Farmas°ytisk nyttige forbindelser
DK249386A (da) Benzoyl-urinstofderivater, fremgangsmaade til fremstilling af saadanne forbindelser og anvendelse af disse som insecticider
DK0404283T3 (da) 11alfa-aryl-4-estrener, fremgangsmåde til fremstilling af disse samt deres anvendelse som lægemidler
DK383388D0 (da) 3-demethyl-4-fluor-mevalonsyrederivater, deres fremstilling, farmaceutiske praeparater deraf, deres anvendelse og mellemprodukter til deres fremstilling
DK0634396T3 (da) Aminosyrederivater og deres anvendelse som enkeltfalinaseinhibitorer
DK0632026T3 (da) Alfa-aminosyrederivater, en fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger, der indeholder dem
NO301826B1 (no) Heterotricyklisk substituerte fenylcykloheksankarboksylsyrederivater, legemidler inneholdende dem og deres anvendelse for fremstilling av legemidler
DK4287A (da) Polyfluoralkylthiomethyl-forbindelser, fremgangsmaade til fremstilling deraf og anvendelse af saadanneforbindelser som overfladeaktive midler
NO933558D0 (no) Benzimidazoler, legemidler inneholdende disse forbindelser, og fremgangsmaate for deres fremstilling
DK0612763T3 (da) Cykliske angiopeptinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
NO871375D0 (no) Bis-tertiaerbutylamino-substituerte 1,3,5-triazinderivater, fremgangsmaate til deres fremstilling, legemidler inneholdende disse forbindelser og deres anvendelse.
DK0519512T3 (da) Mikrobiologisk fremgangsmåde til fremstilling af 5-hydroxypyrazincarboxylsyre
DK0946585T3 (da) Steroidforbindelser substitueret i stilling 11, fremgangsmåde til deres fremstilling, deres anvendelse som lægemidler og farmaceutiske præparater med indhold deraf
SE9803277D0 (sv) Novel compounds
DK73487A (da) Antibiotika af streptogramin-type, mikrobiologisk fremgangsmaade til fremstilling og deres anvendelse som laegemidler og fodertilsaetningsmidler